Cancer Biologics Find Traction with Increasing Prevalence of Cancer and Growing Need for Targeted Therapeutics
The use of cancer biologics is increasing day by day. The increasing cost of medicinal drugs has forced the pharmaceutical industry to develop more advanced tools to produce cost-effective medicines. One such tool is the introduction of bacterial genetic engineering in pharmaceutical productions. This process helps the manufacturers to produce large numbers of therapeutic proteins called interferons and monoclonal antibodies. These medicines can help the patients to fight against the deadliest malignancies like leukemia, cancer, cervical cancer, etc. However, many therapeutic proteins are yet to be produced which can cure cancers.
The search for an alternate therapy for cancer was motivated by the experts when they found out that the existing treatments are either too weak or sometimes the drug itself causes cancer. In order to increase the effectiveness of the drug, cancer biologics were introduced. The most recently introduced biologic drug for the treatment of cancer is ARX788. In January 2021, Ambrx announced that the U.S. Food and Drug Administration granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2 based regimens in the metastatic setting.
Biologic drugs for cancer are those that attack the tumor cells directly. The increasing prevalence of cancer is expected to boost the demand for these drugs. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. The most common and efficient drug used for this purpose is the antineoplastic agents. Monoclonal antibodies are produced by the natural immune system of our body. The resistance against cancer cells is enhanced by the antibodies produced by the body. In order to measure the increasing prevalence of these antibodies against cancer cells, it is necessary to have a reliable bioassay for assessing the increasing prevalence of these antibodies.
A recent analysis showed that the cost of treatment of cancer increased continuously as the percentage of the population exposed to asbestos increases. Moreover, the cost increased tremendously when compared with the expenditures for oncology. Similarly, the intensity of cancer varies significantly according to the stage of the patient at the time of diagnosis. There was a significant difference in the expenditure ratio of oncology and biologic drugs for cancer according to the different stages of the patients. There was a drastic increase in expenditure in the period of follow up in the period of advanced cancer.
Comments
Post a Comment